siRNA-mediated inhibition of the HIV-1 transactivator of transcription
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The HIV-1 tat gene expresses as small regulatory protein plays an essential role in the upregulation
of viral transcription and elongation of viral transcripts, and is necessary for viral replication.
Because of its importance, anti-viral reagents that specifically target and inhibit tat function,
should effectively reduce viral replication. In this study, two anti-tat siRNAs were designed,
synthesized, and cloned into the retroviral vector, pSuper.retro.neo+GFP. These siRNA constructs,
designated pSRNGsi5860 and pSRNGsi5892 were subsequently analyzed for their ability to downregulate luciferase activity in a tat-dependent assay. The results indicated that one of these,
siRNA5892 reduced luicerase expression in a dose-dependent manner.

Introduction
Infection by the Human Immunodeficiency virus (HIV-1)
leads to a gradual loss of immune surveillance due to infection
and loss of the CD4+ T H lymphocyte population [1-3]. The
resulting failure of the immune system, concomitant with the
rise of opportunistic infections, defines the Acquired Immune
Deficiency Syndrome [4]. The current treatment for HIV-1
infection is termed HAART or Highly Active Anti-Retroviral
Treatment and is designed to reduce the viral load by targeting
two important viral functions: reverse transcription (RT) and
virus capsid maturation. Although very effective at reducing
the viral load, this treatment is not curative. Importantly, viral
resistance to these drugs has already developed [5].
Therefore, it is important that research continue into new
ways to inhibit viral replication. Among the possible targets
for new anti-viral inhibitors are a number of non-enzymatic
functions encoded by the HIV genome to control the overall
infection process. Among these genes are nef, rev, tat, vif,
vpr, and vpu [6].
Tat, or trans-activator of transcription, is a viral regulatory
gene required for HIV gene expression [7]. The tat protein
functions by binding to the stem loop of the trans-activation
response region (TAR), which is transcribed within the first
60 nucleotides of all HIV mRNAs [8].
The tat/TAR
interaction promotes the binding of several host transcription
factors, including Cyclin T and CDK9 [9]. Once recruited to
the transcription complex, CDK9 hyperphosphorylates the Cterminal domain of RNA Polymerase II, increasing its
processivity and allowing efficient elongation of viral
transcripts [10]. Because tat plays a major role in the viral
replication process, anti-viral reagents targeting its function
should inhibit HIV replication.
One such group of reagents takes advantage of RNA
interference. RNAi is a naturally occurring cellular process
that is initiated by small, double-stranded RNA molecules that
trigger degradation of homologous mRNAs and lead to gene
silencing [11-13].
The RNAi pathway is initiated by
endogenous or exogenous double-stranded RNAs that are

acted upon by Dicer, a member of the RNase III family of
proteins [14].
Dicer cleaves double-stranded RNAs into
small, ~22 bp siRNA fragments, one strand of which
associates with the Argonaute protein [15]. The siRNA
fragment, in association with Argonaute, binds to the target
mRNA via Watson-Crick base pairing and initiates formation
of the RISC complex [16], which carries out silencing through
a number of mechanisms including target RNA degradation.
It has been shown that siRNAs can be introduced into cells
exogenously and have been used to specifically silence genes
in cell culture and in vivo [17-19]. There are several
advantages to the use of siRNAs to silence gene expression
including (i) silencing can be mediated by relatively low
levels of siRNA expression in target cells, (ii) silencing is
target mRNA specific, (iii) siRNAs are stable in the cell, and
(iv) siRNAs are not likely to induce interferon responses [20,
21].
This paper describes the design, cloning, and initial testing
of two siRNAs targeted to HIV-1 tat mRNA. These siRNA
constructs, designated si5860 and si5892 to denote their target
sequence within the HIV-1 genome, were cloned into the
retroviral vector, pSuper.retro.neo+GFP. This unique vector
was chosen because it was developed to specifically express
siRNAs from the RNA Polymerase III H1 promoter. Initial
testing of these reagents in a transient tat-dependent luciferase
assay indicated that the activity of one, si5892, acted in a dose
dependent manner to decrease HIV tat function.

Materials and Methods
Oligonucleotides and cloning
The tat RNA sequence of the HIV-1 genomic clone NL4-3
(Accession number M19921) was analysed for the presence of
suitable 19 nucleotide siRNA sites. This analysis identified
two such sequences located at nucleotides 5860-5878 and
5892-5910 (Fig. 1A). These sequences were used to generate
two siRNA constructs designated si5860 and si5892 (Fig. 1B).
Two terminal restriction sites, BglII and HindIII were added,
and the two complementary strands of each siRNA construct
were synthesized (si5860 Upper 5’ GAT CCC CTG G AA GCA
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TCC AG GA AGT CTT CAA GAG AGA CTT CCT GGA TGC TT C
CAT TTT TA 3’, si5860 Lower 5’ AGC TTA AAA ATG GAA GCA
TCC AGG AAG TCT CTC TTG AAG ACT TCC TGG ATG CTT
CCA GGG 3’, si5892 Upper 5’GAT CCC CTT GTA CCA ATT GCT
ATT GTT TCA AGA GAA CAA TAG CAA TTG GTA CAA TTT
TTA 3’ and si5892 Lower 5’AGC TTA AAA ATT GTA CCA ATT
GCT ATT GTT CTC TTG AAA CAA TAG CAA TTG GTA CAA
GGG 3’).

A. HIV-1 Tat Exon One
5830
5840
5850
5860
atggagccag tagatcctag actagagccc tggaagcatc
5870
5880
5890
5900
caggaagtca gcctaaaact gcttgtacca attgctattg
5910
5920
5930
5940
taaaaagtgt tgctttcatt gccaagtttg tttcatgaca
5950
5960
5970
5980
aaagccttag gcatctccta tggcaggaag aagcggagac
5990
6000
6010
6020
agcgacgaag agctcatcag aacagtcaga ctcatcaagc
6030
6040
ttctctatca aagcag

B. Anti-tat si5860 Design
Sense sequence

Hairpin

Antisense sequence

TGGAAGCATCCAGGAAGTCttcaagagaGACTTCCTGGATGCTTCCA
|||||||||||||||||||||||||||||||||||||||||||||||
ACCTTCGTAGGTCCTTCAGaagttctctCTGAAGGACCTACGAAGGT

Figure 1. HIV-1 tat sequence and siRNA design. (A) The HIV-1 NL4-3
tat exon 1 provirus sequence was analysed for potential siRNA target
sites. This analysis revealed two regions (5860-5878 and 5892-5910) that
were used to create siRNA constructs. (B) Using a published model for
siRNA design (Oligoengine), each 19 nucleotide target sequence was
used to produce a double-stranded DNA construct. For this the tat target
sequence (sense) and its inverted complementary sequence (antisense)
were connected by a short hairpin sequence. BglII and HindIII sites (not
shown) were added to each end of the construct to facilitate cloning into
the pSuper.retro.neo+GFP vector. The siRNA shown is targeted to the tat
RNA sequence at 5860. A second siRNA, si5892 was similarly designed.
The sequence located at 6010-6028 was scrambled and used to generate
the control siRNA construct, pSRNGsiCtrl.

Each upper and lower oligonucleotide set was combined in
50 µl Annealing Buffer (100mM NaCl, 50mM HEPES buffer
(pH 7.4)) and cooled slowly from 90˚C to 4˚C. Each of the
resulting siRNA constructs was cloned into the BglII and
HindIII sites of the retroviral vector pSuper.retro.neo+GFP
(Oligoengine), which has been shown to effectively express
siRNAs from an internal RNA Polymerase III H1 promoter
[22]. In preparation for cloning each siRNA, the pSuper
plasmid was digested with BglII and HindIII. The digested
vector fragment was subsequently isolated by gel
electrophoresis. Ligation reactions were carried out using T4
DNA Ligase (Promega) at 4ºC overnight.
The ligated
plasmids were transformed into SURE competent cells

(Stratagene) and the resulting colonies were analysed for
siRNA presence. For this, miniprep DNA [23] was screened
by PCR using a plasmid-specific primer pair that framed the
cloning site. Positive clones were indicated by the presence
of a 499 bp fragment. Correct siRNA insertion into the
resulting plasmids, pSRNGsi5860 and pSRNGsi5892, was
verified by sequencing.
Cell lines and transfections
293T cells were grown in standard medium consisting of
Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% Fetal Bovine Serum (FBS), 1% L-glutamine, and
1% penicillin-streptomycin. The cells were maintained in a
humidified 37°C incubator with 5% CO 2. All transfections
were done by calcium phosphate precipitation based on the
method of Chen and Okayama [24]. Briefly, 293T cells were
plated to 50-70% confluency 24 hours prior to transfection.
The cells were transiently transfected with plasmid DNA in
125 mM CaCl2, and 2X BBS (280 mM NaCl/ 1.5 mM
Na2HPO 4/ 50 mM N-,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) (pH 7.05)). The plasmid mixture was
incubated at room temperature for approximately 10 minutes,
and the entire volume was added to the culture medium. The
medium was replaced 24 hours post-transfection, and the cells
were incubated for a further 24 hours. Forty-eight hours posttransfection, the cells were assayed for siRNA activity.
siRNA-mediated anti-tat activity
Anti-tat siRNA activity was accessed in transiently
transfected 293T cells expressing the luciferase reporter gene
from the HIV-1 genomic clone pNL4-3.Luc.R -.E - [25, 26],
which is replication incompetent due to two frameshifts that
rendered the clone env- and vpr-. In addition, the firefly
luciferase gene was inserted into the pNL4-3 nef gene. In this
plasmid, luciferase expression is driven by the HIV-1
promoter and is therefore tat-dependent. To determine the
anti-tat activity of the cloned siRNAs, 293T cells were plated,
1x106 per well, in 60 mm dishes. After 24 hours, the cells
were transfected with 2 µg pNL4-3.Luc.R -.E - and either 2 µg
or 4 µg of pSRNGsi5860, pSRNGsi5892, or pSRNGsiCtrl, a
previously cloned control siRNA targeted to the scrambled
HIV-1 tat sequence located at 6010-6028 (Fig. 1A). These
transfection mixtures resulted in a 1:1 or 1:2 HIV-1 to siRNA
plasmid ratio allowing dose-dependent siRNA activity to be
measured. Transfection efficiency was analysed 48 hours
post-transfection by observing GFP expression using an
Olympus CKX41 inverted microscope with epifluorescence.
Luciferase activity was analysed using the Steady-Glo
Luciferase kit (Promega). Briefly, 48 hours post-transfection,
the medium was removed from the transfected cells and
replaced with 1.1 ml Glo Lysis buffer. Each plate was rocked
briefly to ensure complete coverage of the lysis buffer and
then incubated at room temperature for five minutes. The cell
lysate was centrifuged to remove cell debris and aliquoted
into multiple 1.5 ml tubes. Protein samples were stored at 80°C until analysed. The protein concentration of each
sample was determined using a BCA protein assay (Pierce),
and luciferase activity was measured in 50 µg total protein.
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The assay was conducted in a 96-well format and included
three measurements of each sample taken from two
independent experiments. Luciferase activity was reported in
relative light units (RLU) as measured using a Genios
luminometer (Tecan).

Results
The HIV-1 NL4-3 tat genomic sequence was analysed for the
presence of potential siRNA target sites. Two sites were
identified and used to generate siRNA constructs. The sense
and antisense strand corresponding to each siRNA was
synthesized, annealed, and cloned into the retroviral vector,
pSuper.retro.neo+GFP. PCR screening was used to identify
siRNA-positive clones that were subsequently sequenced to
verify insertion of the specific siRNA construct.
The
resulting plasmids were designated pSRNGsi5860 and
pSRNGsi5892. Successful cloning of si5860 and si5892
placed each under control of the RNA Polymerase III H1
promoter (Fig. 2). In addition, each siRNA vector expresses
neomycin phosphotransferase and the green fluorescent
protein (GFP) from a single transcript separated by an internal
ribosome entry site and under the control of the
phosphoglycerokinase promoter (Fig. 2).

Figure 2. Generation of anti-tat siRNA retroviral vectors. Two siRNAs
designed to target the HIV-1 tat mRNA at nucleotides 5860-5878 and
5892-5910 were synthesized and cloned into the retroviral vector,
pSuper.retro.neo+GFP. The pSRNGsi5860 plasmid map is shown.

To determine the ability of the constructs to inhibit tat
expression, each siRNA-expression plasmid was cotransfected into 293T cells along with the HIV-1 genomic
clone, pNL4-3.Luc.R -.E -.
In this plasmid, luciferase
expression is under the control of the HIV promoter/enhancer
and is therefore tat-dependent. For this assay 293T cells were
transiently co-transfected with 2 µg of pNL4-3.Luc.R -.E - and
either 2 µg or 4 µg of pSRNGsi5960, pSRNGsi5892, or
pSRNGsiCtrl. Therefore the plasmid ratio of HIV-1 to siRNA
was either 1:1 or 1:2, allowing a determination to be made
regarding any dose dependency of the siRNA constructs.
Transfection efficiency, which was evaluated visually by
observing GFP expression, suggested that reporter gene
expression was higher in the 1:2 ratio transfections (Fig.3 B,
D, and F) as compared to the 1:1 ratio transfections (Fig. 3 A,
C, and E).

Figure 3. Analysis of transfection efficiency. 293T cells were transiently
transfected with 2 µg pNL4-3.Luc.R-E- and either 2 µg or 4 µg of each
siRNA-expression plasmid. (A, B). 2 µg and 4 µg pSRNGsiCtrl. (C, D).
2 µg and 4 µg pSRNGsi5860. (E, F). 2 µg and 4 µg pSRNGsi5892.
Forty-eight hours post-transfection, cells were observed for GFP
expression as an indication of transfection efficiency. This analysis
indicated efficient transfection and suggested increased GFP expression
in cells transfected at the 1:2 plasmid ratio.

To measure luciferase activity, transfected cells were lysed
to obtain total cytoplasmic protein. Six 50 µg total protein
samples, three samples taken from each of two independent
experiments, were analysed to determine the relative
luciferase activity associated with each HIV-1/siRNA plasmid
combination. The results of these tests indicated that si5892
was active against tat in a dose dependent manner (Fig. 4,
pSRNGsi5892). To this end, 293T cells transfected at a 1:2
HIV-1/5892siRNA plasmid ratio showed a significantly lower
luciferase activity than identical cells transfected at a 1:1
HIV-1/5892 siRNA ratio (p = 0.002). In comparison, 293T
cells transfected at a 1:2 HIV-1/5860siRNA plasmid ratio did
not indicate significantly different luciferase activity as
compared to the cells transfected at a 1:1 HIV-1/si5860
plasmid ratio. However, luciferase activity at the 1:2 plasmid
ratio trended lower than that of the 1:1 plasmid ratio (Fig. 4,
pSRNGsi5860).
Additionally, the control siRNA
(pSRNGsiCtrl) showed no dose-dependent activity.

Figure 4. Anti-tat siRNA luciferase assay. 293T cells were transiently
transfected with 2 µg of the HIV-1 genomic clone pNL4-3.Luc.R-.E- and
either 2 µg or 4 µg of the siRNA-expression plasmids, pSRNGsiCtrl,
pSRNGsi5860, or pSRNGsi5892. Luciferase activity was measured 48
hours post-transfection in transfected cell lysates. This analysis indicated
a significant dose dependent decrease in luciferase activity as a function
of pSRNGsi5892 plasmid levels (p = 0.002). No significant differences
in luciferase activity were observed with pSRNGsiCtrl or pSRNGsi5860.
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Each measurement represents the mean and standard error from six
samples taken from two independent experiments.

Conclusions
The primary goal of this project was to design and clone two
siRNA constructs targeted to HIV-1 tat. Subsequently, an
analysis of the HIV-1 tat genomic sequence revealed two
potential siRNA target sites located at nucleotides 5860-5878
and 5892-5910, respectively (Fig. 1). To determine which of
these sequences provides a more attractive target, each of the
19-nucleotide sequences was integrated into a siRNA model
based on the Oligoengine design for cloning into their
retroviral vector, pSuper.retro.neo+GFP. The resulting DNA
oligonucleotides were synthesized and cloned to create the
siRNA constructs, pSRNGsi5860 and pSRNGsi5892 (Fig 2.)
The relative anti-tat activity of these siRNA constructs was
tested in a transient assay in which each was co-transfected
along with the HIV-1 genomic clone, pNL4-3.Luc.R -.E -. In
this plasmid, luciferase expression is under control of the
HIV-1 promoter and is therefore tat-dependent.
Cotransfections with pNL4-3.Luc.R-.E- and the siRNA plasmids
at either a 1:1 or a 1:2 plasmid ratio indicated that one si5892,
acted in a dose dependent manner to reduce luciferase activity
(Fig. 4). In comparison, si5860, showed no significant ability
to reduce luciferase activity in a dose-dependent manner.
Co-transfection of pNL4-3.Luc.R -.E - with anti-tat reagents,
such as the siRNA constructs described here, provides a
convenient and relatively simple assay to determine the
effectiveness of such reagents without the need for more
elaborate methods. However, because this is an indirect
measure of anti-tat activity, follow-up analyses must be made
to verify these results. There are a number of factors that may
impact the relative activity of the siRNAs in this system.
Primarily, the transient nature of the experiment makes it
difficult to control plasmid uptake by the transfected cells. It
is likely that some cells have altered HIV-1/siRNA plasmid
ratios. However, the variation among the samples was
relatively small, indicating that this assay is a reasonable
system for initial screening of anti-HIV siRNAs. In addition
to determining if either siRNA construct act directly on tat, it
will also be important to test the ability of the pSuper vectors
to generate retroviral particles to deliver the siRNA
constructs. These assays will allow a more realistic check of
siRNA activity and potential efficacy.
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